Open questions on vorasidenib

While vorasidenib is becoming the first-line treatment in the majority of IDH-mutant grade 2 gliomas, we are progressively learning how it works, how it should be used and in which contexts beyond grade 2 IDH-mutant gliomas it could be beneficial.

Authors

François Ducray (ORCID: https://orcid.org/0000-0002-8150-5785)
Antoine Seyve (ORCID: https://orcid.org/0000-0002-8533-3976)

Institutions

Hospices Civils de Lyon (FR)
Centre de Recherche en Cancérologie de Lyon (FR)

Publication Details

Journal: Current Opinion in Oncology
Published: 2025-09-12
DOI: https://doi.org/10.1097/cco.0000000000001193
Citations: 1
Primary Topic: Glioma Diagnosis and Treatment
Type: article
Field-Weighted Citation Impact: 1.63

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Open questions on vorasidenib

François Ducray, Antoine Seyve

Sep 12, 2025

1 citations

Current Opinion in Oncology

Glioma Diagnosis and Treatment

1.63

article

Open questions on vorasidenib

François Ducray, Antoine Seyve

September 12, 2025article en

1 citations

Abstract

Current Opinion in OncologyVol. 37(6)

Hospices Civils de Lyon (FR), Centre de Recherche en Cancérologie de Lyon (FR)

Openalex Percentile: Top 13%

Glioma Diagnosis and Treatment

1.63

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Open questions on vorasidenib — François Ducray, Antoine Seyve · Current Opinion in Oncology (2025) | TGRS Research Map | TGRS